Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences

BOSTON, March 01, 2023 (GLOBE NEWSWIRE) --  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will take part in two investor healthcare conferences in March, the Cowen 43rd Annual Health Care Conference being held in Boston, Massachusetts March 6-8, 2023, and the Oppenheimer 33rd Annual Healthcare Conference being held virtually March 13-15, 2023.

The company will provide a corporate overview highlighting recent progress from their IL-2-based CUE-100 series of biologics. This will include discussions on its ongoing Phase 1 trials evaluating its lead drug candidate, CUE-101, in HPV+ recurrent/metastatic head and neck cancer as a monotherapy and in combination with pembrolizumab (KEYTRUDA^®), as well as their second clinical drug candidate, CUE-102, currently being evaluated in a Phase 1 trial for the treatment of Wilms’ Tumor 1 (WT1) positive cancers. The company will also discuss their newly established partnership with Ono Pharmaceutical to help advance Cue Biopharma’s lead autoimmune disease asset, CUE-401, toward the clinic.

Presentation Details:

Cowen 43rd Annual Health Care Conference

Date and Time: Tuesday, March 7 at 11:10 a.m. to 11:40 a.m. ET

Webcast Link: 

Presenter: Daniel Passeri, chief executive officer, Cue Biopharma

Oppenheimer 33rd Annual Healthcare Conference

Date and Time: Wednesday, March 15 at 12:00 p.m. to 12:30 p.m. ET

Webcast Link:

Presenter: Daniel Passeri, chief executive officer, Cue Biopharma

Live and archived webcasts of the presentations will be available on the Events page in the Investors and Media section of the Company’s website at . The webcasts will be archived for 30 days.

About Cue Biopharma

Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the body’s intrinsic immune system as T cell engagers without the need for ex vivo manipulation or broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information please visit  and follow us on Twitter at .

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the potential benefits and results that may be achieved through the collaboration with Ono; the company’s belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective engagement of disease-relevant T cells; and the company’s business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s limited operating history, limited cash and a history of losses; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the company’s trials; negative or inconclusive results from the company’s clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future; operations and clinical the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Contact

Marie Campinell

Senior Director, Corporate Communications

Cue Biopharma, Inc.

 

Media Contact

Maya Romanchuk

LifeSci Communications